Prelude Therapeutics Inc — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
Prelude Therapeutics reported Q2 2026 net loss of $13.9M ($0.14/share) on $5.7M revenue, down from $31.2M loss ($0.41/share) year-ago. Cash and marketable securities totaled $155.2M as of June 30, 2026, funding operations into Q2 2028. Key milestones: PRT13722 (KAT6A degrader) Phase 1 initiation expected Q4 2026 in HR+ breast cancer; PRT12396 (JAK2V617F inhibitor) Phase 1 enrolling in PV/MF; mCALR DAC program advancing; CMO Charles Morris appointed April 2026.
Why this rating
Routine biotech quarterly results. $155M cash is ~11× market cap, extending runway 18+ months—positive. Q2 net loss improved but still substantial relative to size. Pipeline on track but no clinical data. No transformational event.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.